Objective - is to assess lipid levels and identify polymorphism of the FGB fibrinogen gene in patients with arterial hypertension (AH). Materials and methods. The study included 76 patients with AH (main group) and 24 patients without this pathology (control group). The main group was divided into 3 clinical groups: the 1stgroup included 29 patients with hypertension, the 2nd group - 23 patients with hypertension and coronary heart disease, the 3rd group - 24 patients with a combination of AH with CAD and type 2 DM. The number of platelets in the blood, body mass index (BMI), blood pressure (SBP/DBP) was measured. The concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) were determined in the blood using test kits. The level of very low lipoprotein cholesterol (VLDL-C) and low-density lipoprotein cholesterol (LDL-C) and the atherogenic index (AI) were calculated using the formulas. Determination of the polymorphism of the fibrinogen gene FGB in the blood was carried out by mass spectrometry (MALDI-TOF) on a Seguenon mass spectrometer (USA). Statistical analysis included mean, standard deviation, Fisher’s test (F), χ2 method with Yates correction, odds ratio (ORodds ratio) with 95% confidence interval. Results. Hypercholesterolemia in the 1st group was detected in 48.3% of cases, in the 2nd and 3rd groups - 43.5% and 37.5%, respectively. Hypertriglyceridemia in 1st, 2nd and 3rd groups was observed in 51.7%, 39.1% and 50.0%, respectively. The prevalence of the G/G genotype among patients with AH was 69.0%, among patients with AH and CAD - 87.0%, and in patients with AH and CAD and DM - 58.3%. The heterozygous genotype G/A among patients of the 3rd group was found in 33.3%, the 1st group - in 24.1% and the 2nd group - in 4.3%. The A/A genotype were detected in the 1st, 2nd and 3rd groups in 6.9%, 8.7% and 8.3% of cases, respectively. Conclusion. The dominant type of dyslipidemia was hypertriglyceridemia. Heterozygous G/A genotype was more common in patients with AH, CAD and DM compared to patients with AH and CAD (p<0.05). The chance of meeting patients with heterozygous G/A genotype among patients with AH is 7 times higher (p<0.05). Welldesigned large-scale studies in larger populations are needed to confirm this finding.